Galectin Therapeutics Company Profile (NASDAQ:GALT)

Analyst Ratings

Consensus Ratings for Galectin Therapeutics (NASDAQ:GALT) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $12.00 (631.71% upside)

Analysts' Ratings History for Galectin Therapeutics (NASDAQ:GALT)
Show:
DateFirmActionRatingPrice TargetActions
7/1/2016Roth CapitalInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/19/2016FBR & CoReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/12/2016HC WainwrightReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/12/2015MLV & Co.Reiterated RatingBuy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/1/2014AegisDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/30/2014 forward)

Earnings

Earnings History for Galectin Therapeutics (NASDAQ:GALT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/10/2016Q1($0.17)($0.24)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/15/2016Q415($0.22)($0.19)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q3($0.20)($0.26)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q2($0.23)($0.21)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q115($0.20)($0.22)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/18/2015($0.17)($0.18)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q314($0.27)($0.17)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q214($0.21)($0.17)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2014Q114($0.20)($0.27)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/21/2014($0.18)($0.15)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2013Q3($0.18)($0.22)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/14/2013Q213($0.19)($0.18)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/10/2013Q1 2013($0.18)($0.22)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2012Q312($0.18)($0.19)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Galectin Therapeutics (NASDAQ:GALT)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.22)($0.22)($0.22)
Q2 20162($0.24)($0.22)($0.23)
Q3 20162($0.25)($0.22)($0.24)
Q4 20162($0.24)($0.22)($0.23)
Q1 20171($0.22)($0.22)($0.22)
Q2 20171($0.22)($0.22)($0.22)
Q3 20171($0.22)($0.22)($0.22)
Q4 20171($0.22)($0.22)($0.22)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Galectin Therapeutics (NASDAQ:GALT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Galectin Therapeutics (NASDAQ:GALT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
1/5/2016Arthur GreenbergDirectorBuy1,666$1.72$2,865.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2015Peter G TraberCEOBuy2,000$2.00$4,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015Kevin D FreemanDirectorBuy2,083$2.70$5,624.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015Peter G TraberCEOBuy4,000$2.53$10,120.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/19/2014Arthur GreenbergDirectorBuy1,000$4.56$4,560.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/15/2014Kevin D FreemanDirectorBuy1,000$4.70$4,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2014Jack W CallicuttCFOBuy1,000$4.55$4,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2014Peter G TraberCEOBuy4,000$4.46$17,840.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2014Peter G TraberCEOBuy1,000$4.42$4,420.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/11/2014Steven PrelackDirectorSell6,000$11.84$71,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/13/2014James C CzirrChairmanSell100,000$14.84$1,484,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/4/2013Marc RubinDirectorBuy3,000$8.69$26,070.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2013Arthur GreenbergDirectorBuy2,000$6.55$13,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2013Peter G TraberCEOBuy1,000$5.53$5,530.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/18/2013Peter G TraberCEOBuy1,000$5.80$5,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/15/2013James C CzirrChairmanBuy1,000$6.90$6,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2013John F MauldinDirectorBuy1,176$4.21$4,950.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/28/2013Kevin D FreemanDirectorBuy1,000$4.21$4,210.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/12/2012Peter G TraberCEOBuy2,500$2.11$5,275.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/9/2012Peter G TraberCEOBuy2,500$2.00$5,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/8/2012Peter G TraberCEOBuy5,000$2.07$10,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Galectin Therapeutics (NASDAQ:GALT)
DateHeadline
07/30/16 07:01 AMCan Shares Of Galectin Therapeutics Inc. (NASDAQ:GALT) Hit $12? - Investor Newswire
07/28/16 04:02 AMNonalcoholic steatohepatitis market: major regions: North America, Europe, Asia Pacific, Latin America, and Middle East and Africa
07/24/16 03:52 PMIs $12 Price Target Attainable For Galectin Therapeutics Inc. (NASDAQ:GALT)? - Investor Newswire
07/22/16 07:02 AMGalectin Therapeutics Incorporated (NASDAQ:GALT) Short Interest Increased By 6.77% - Consumer Eagle
07/16/16 03:58 PMShares Moving Down on the Week: Galectin Therapeutics, Inc. (NASDAQ:GALT) - Engelwood Daily
07/16/16 07:33 AMStrong Sell Calls For Galectin Therapeutics Inc. (NASDAQ:GALT) At 0 - Investor Newswire
07/15/16 03:08 PMDoes Galectin Therapeutics Inc Have Any Gas After Forming This Ascending Triangle Pattern? - Consumer Eagle
07/14/16 04:16 PMGalectin Therapeutics Incorporated (NASDAQ:GALT) Short Interest Decreased By 10.69% - Consumer Eagle
07/14/16 07:30 AMBroker Outlook For Galectin Therapeutics Inc. (GALT) - Fiscal Standard
07/13/16 04:29 PMGalectin Therapeutics (GALT) Announces Australian Notice of Patent for GR-MD-02
07/13/16 08:08 AMPeter G. Traber, M.D., CEO and CMO of Galectin Therapeutics, to Speak on the Medical Applications of Plant-Derived Complex Carbohydrates - [at noodls] - Dr. Traber to speak on Galectin Therapeutics' Development of GR-MD-02 for treatment of human disease NORCROSS, Ga.--(BUSINESS WIRE)-- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of ...
07/12/16 09:29 PMGalectin Therapeutics (GALT) Announces Australian Notice of Patent for GR-MD-02 - StreetInsider.com
07/12/16 08:03 AMGalectin Therapeutics Receives Notice of Australian Patent to be Granted for the Use of GR-MD-02 in Liver, Kidney, Lung or Heart Fibrosis - [at noodls] - NORCROSS, Ga.--(BUSINESS WIRE)-- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the Company ...
07/11/16 04:11 PMGalectin Therapeutics Inc (NASDAQ:GALT) Q1 2016 Sentiment - Consumer Eagle
07/10/16 08:36 AMGalectin Therapeutics Inc. (GALT) Broker Price Targets For The Coming Week - Fiscal Standard
07/09/16 03:50 PMIs $12 Within Reach For Galectin Therapeutics Inc. (NASDAQ:GALT)? - Investor Newswire
07/06/16 04:16 PMGalectin Therapeutics Incorporated (NASDAQ:GALT) Shorted Shares Decreased By 10.69% - Press Telegraph
07/06/16 08:51 AMProtein target may block deadly arterial remodeling in pulmonary hypertension
07/05/16 08:51 AMBroker Outlook For The Week Ahead Galectin Therapeutics Inc. (GALT) - Fiscal Standard
07/02/16 07:03 AMGalectin Therapeutics Inc. (NASDAQ:GALT) Expected to Reach Highs Of $12 - Investor Newswire
07/01/16 04:44 AMGalectin Therapeutics Incorporated (NASDAQ:GALT) Sellers Covered 10.69% of Their Shorts - Engelwood Daily
07/01/16 04:44 AMGalectin Therapeutics Inc. (GALT) Jumps 5.37% on June 29 - Equities.com
06/30/16 04:38 AMNew Broker Ratings For Galectin Therapeutics Inc. (GALT) - FTSE News
06/26/16 03:40 PMShare Volatility Check for: Galectin Therapeutics, Inc. (NASDAQ:GALT) - Press Telegraph
06/26/16 03:40 PMStrong Sell Calls Recommendations For Galectin Therapeutics Inc. (NASDAQ:GALT) At 0 - Investor Newswire
06/26/16 03:40 PMGalectin Therapeutics Inc. (GALT) Jumps 6.9% on June 24 - Equities.com
06/23/16 07:04 AMGalectin Therapeutics Inc. (GALT) Updated Price Targets - FTSE News
06/21/16 03:53 PMThis Weeks Broker Views For Galectin Therapeutics Inc. (GALT) - Fiscal Standard
06/20/16 03:58 PMGALECTIN THERAPEUTICS INC : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
06/20/16 03:32 PMGALECTIN THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exh -
06/19/16 08:29 AMStrong Buy Calls Count For Galectin Therapeutics Inc. (NASDAQ:GALT) At 2 - Investor Newswire
06/16/16 04:10 PMRecently Issued Stock Ratings For Galectin Therapeutics Inc. (GALT) - Fiscal Standard
06/06/16 09:35 PMPNM Resources, Inc. (NYSE:PNM) Increased 1.84%: Galectin Therapeutics, Inc. (NASDAQ:GALT), AbbVie Inc. (NYSE ... - KC Register
06/02/16 04:22 PMGalectin Therapeutics (GALT) Announces Positive GR-MD-02 Preclinical Data in PAH - StreetInsider.com - Galectin Therapeutics (GALT) Announces Positive GR-MD-02 Preclinical Data in PAHStreetInsider.comGalectin Therapeutics, Inc. (Nasdaq: GALT) reports that GR-MD-02, its development-stage galectin-3 (gal-3) inhibitor, has shown a positive effect on vascular remodeling in an animal model of pulmonary arterial hypertension (PAH). The results were ...Galectin Therapeutics Reports Positive Preclinical Results on GR-MD-02 For Pulmonary Arterial Hypertension ...Sonoran Weekly Reviewall 3 news articles »
06/02/16 07:15 AMGalectin Therapeutics Announces Positive Preclinical Results on the Role of Galectin-3 in Mediating Vascular Remodeling in Pulmonary Arterial Hypertension - [at noodls] - NORCROSS, Ga., June 02, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, reports that ...
05/31/16 04:17 PMStrong Sell Calls Count For Galectin Therapeutics Inc. (NASDAQ:GALT) At 0 - Investor Newswire - Strong Sell Calls Count For Galectin Therapeutics Inc. (NASDAQ:GALT) At 0Investor NewswireGalectin Therapeutics Inc. (NASDAQ:GALT) has a total of 2 Strong Buy calls and 0 Strong Sell advises as of 2016-05-30. Zacks uses a rating procedure which assigns scores to stocks on a narrow 1-5 scale. When a stock gets a score of 1 or 2, it is ...and more »
05/29/16 12:04 AMGalectin Therapeutics Incorporated (NASDAQ:GALT) Sellers Increased By 5.45% Their Shorts - HNN - Galectin Therapeutics Incorporated (NASDAQ:GALT) Sellers Increased By 5.45% Their ShortsHNNThe short interest to Galectin Therapeutics Incorporated's float is 3.18%. The stock increased 4.96% or $0.07 on May 27, hitting $1.48. About 39,233 shares traded hands. Galectin Therapeutics Inc (NASDAQ:GALT) has declined 46.38% since October 22, ...After Recent Decline, is it Time to Sell Galectin Therapeutics, Inc. (NASDAQ:GALT)Franklin Independentall 2 news articles »
05/23/16 12:17 PMAfter Last Week What Do Analysts Think Of Galectin Therapeutics Inc. (GALT) - Share Trading News - After Last Week What Do Analysts Think Of Galectin Therapeutics Inc. (GALT)Share Trading News10/07/2013 – Ascendiant Capital Markets began new coverage on Galectin Therapeutics Inc. giving the company a “buy” rating. They now have a USD 13 price target on the stock. The share price of Galectin Therapeutics Inc. (GALT) was down -0.65% during ...
05/20/16 06:58 PMRevenue Update on Galectin Therapeutics Inc(NASDAQ:GALT) - Trade Calls - Revenue Update on Galectin Therapeutics Inc(NASDAQ:GALT)Trade CallsGalectin Therapeutics Inc(NASDAQ:GALT) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during After-hours on May 10, 2016. Earnings per share were $-0.24. Analysts had estimated an EPS of $-0.17. In a different note, On ...Galectin Therapeutics Inc. (GALT) Updated Broker Price TargetsShare Trading NewsGalectin Therapeutics Incorporated (NASDAQ:GALT) Sellers Covered 6.83% of Their ShortsWall Street Hints and NewsAnalysts Offer Insights on Healthcare Companies: Galectin Therapeutics (GALT) (NASDAQ: GALT), Mazor Robotics ...Analyst Ratingsall 4 news articles »
05/19/16 06:59 PMGalectin Therapeutics Incorporated (NASDAQ:GALT) Sellers Covered 6.83% of Their Shorts - Wall Street Hints and News - Galectin Therapeutics Incorporated (NASDAQ:GALT) Sellers Covered 6.83% of Their ShortsWall Street Hints and NewsThe short interest to Galectin Therapeutics Incorporated's float is 3.11%. The stock is up 5.44% or $0.08 after the news, hitting $1.55 per share. About 88,050 shares traded hands. Galectin Therapeutics Inc (NASDAQ:GALT) has declined 43.24% since ...Analysts Offer Insights on Healthcare Companies: Galectin Therapeutics (GALT) (NASDAQ: GALT), Mazor Robotics ...Analyst Ratingsall 2 news articles »
05/19/16 12:04 PMGALECTIN THERAPEUTICS INC Financials -
05/18/16 11:26 AMNanocap Volatile Stocks: Galectin Therapeutics (NASDAQ:GALT), NovaBay Pharmaceuticals (NYSEMKT:NBY ... - KC Register - Nanocap Volatile Stocks: Galectin Therapeutics (NASDAQ:GALT), NovaBay Pharmaceuticals (NYSEMKT:NBY ...KC RegisterGalectin Therapeutics, Inc. (NASDAQ:GALT) announces positive interim results from an exploratory, open-label, Phase 2a clinical trial with GR-MD-02 in patients with moderate-to-severe plaque psoriasis. All four patients who received 12 weeks of therapy ...and more »
05/16/16 06:43 PMGalectin Therapeutics (GALT) Offers Positive Update from GR-MD-02 Phase 2a - StreetInsider.com - Galectin Therapeutics (GALT) Offers Positive Update from GR-MD-02 Phase 2aStreetInsider.comGalectin Therapeutics Inc. (NASDAQ: GALT) announces positive interim results from an exploratory, open-label, Phase 2a clinical trial with GR-MD-02 in patients with moderate-to-severe plaque psoriasis. All four patients who received 12 weeks of therapy ...and more »
05/16/16 04:24 PM5:24 pm Galectin Therapeutics announces 'positive' interim results from Phase 2a clinical trial with GR-MD-02 -
05/16/16 03:22 PMGalectin Therapeutics Announces Positive Interim Results from Phase 2a Trial with GR-MD-02 in Moderate-to-Severe Plaque Psoriasis - [at noodls] - A significant clearing of psoriasis in first four patients prompts the extension of treatment for an additional 12 weeks Conference call to be held tomorrow at 9:00 a.m. Eastern time NORCROSS, Ga., May ...
05/14/16 12:32 AMEnrollment in NASH-FX trial for advanced fibrosis, NASH complete - Galectin Therapeutics Inc. announced enrollment is complete for its phase 2 NASH-FX trial investigating GR-MD-02, a complex carbohydrate drug that targets galectin-3, for the treatment of nonalcoholic steatohepatitis and advanced fibrosis. The study ...
05/13/16 12:52 AMGalectin Therapeutics Inc. (GALT) Jumps 11.59% on May 11 - Equities.com - Galectin Therapeutics Inc. (GALT) Jumps 11.59% on May 11Equities.comGalectin Therapeutics Inc. (GALT) was among the biggest gainers on the Russell 2000 for Wednesday May 11 as the stock popped 11.59% to $1.54, representing a gain of $0.16 per share. Some 197,357 shares traded hands on 513 trades, compared with an ...and more »
05/11/16 07:43 PMGalectin Therapeutics (GALT) Completes Enrollment in Phase 2 Trial with GR-MD-02 in NASH - StreetInsider.com - Galectin Therapeutics (GALT) Completes Enrollment in Phase 2 Trial with GR-MD-02 in NASHStreetInsider.comGalectin Therapeutics Inc. (NASDAQ : GALT) announces the completion of enrollment in its Phase 2 clinical trial with GR-MD-02 in patients with non-alcoholic steatohepatitis (NASH) with advanced fibrosis (stage 3) (the NASH-FX trial). The Company ...Top News: Galectin Therapeutics, Inc. (NASDAQ:GALT), Nautilus Inc. (NYSE:NLS), Newmont Mining Corporation ...KC RegisterGalectin Therapeutics Completes Enrollment for Trial of GR-MD-02 in Fibrosis Patients; Shares Jump 16% Early ...Sonoran Weekly ReviewGalectin Therapeutics hits enrollment target in mid-stage NASH study of lead product candidate, top-line data ...Seeking Alphaall 5 news articles »
05/11/16 06:52 AMGALECTIN THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
05/10/16 06:53 AMGALECTIN THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and -

Social

About Galectin Therapeutics

Galectin Therapeutics logoGalectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company's galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: GALT
  • CUSIP:
Key Metrics:
  • Previous Close: $1.57
  • 50 Day Moving Average: $1.50
  • 200 Day Moving Average: $1.42
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $47.53M
  • Beta: 1.42
  • Current Year EPS Consensus Estimate: $-0.97 EPS
  • Next Year EPS Consensus Estimate: $-0.95 EPS
Additional Links:
Galectin Therapeutics (NASDAQ:GALT) Chart for Saturday, July, 30, 2016